Neuromodulation has the capacity to address acute and chronic effects of COVID-19

The ICNC was established in early 2020 in response to the SARS-CoV-2 pandemic, and the realization that many critically ill patients suffering from COVID-19, the disease caused by the novel coronavirus, were experiencing systemic hyperinflammation, organ failure, shock, and death.

  MISSION
 

Provide global leadership for the rapid advancement and clinical adoption of neuromodulation technologies to treat emerging infectious diseases.

  VISION
 

A global infrastructure capable of the rapid deployment and clinical validation of neuromodulation technologies for pandemics, epidemics, and other emerging public health crises for which they may be efficacious.

Screen Shot 2020-05-15 at 8.17.46 AM
Screen Shot 2020-05-15 at 8.17.46 AM

press to zoom
Image 5-22-20 at 10.25 AM
Image 5-22-20 at 10.25 AM

press to zoom
Screen Shot 2020-05-15 at 8.17.46 AM
Screen Shot 2020-05-15 at 8.17.46 AM

press to zoom
1/2

ICNC Founding Members

Screen Shot 2020-05-21 at 1.46.00 PM.png

MAROM BIKSON, PhD

Professor, Biomedical Engineering

The City College of New York

Screen Shot 2020-05-21 at 1.50.43 PM.png

JIANDE CHEN, PhD

Professor of Medicine

Director, Neuromodulation

University of Michigan School of Medicine

Screen Shot 2020-05-22 at 6.58.18 AM.png

CHRIS CZURA, PhD

Co-Founder and Chief Scientist

Convergent Medical Technologies, Inc.

Screen Shot 2020-05-21 at 1.51.53 PM.png

MANFRED FRANKE, PhD

CEO, Founder 

Neuronoff, Inc.

Screen Shot 2020-05-21 at 1.55.39 PM.png

ERIC GRIGSBY, MD, MBA

President and CEO

Neurovations

Screen Shot 2020-05-21 at 1.57.30 PM.png

SAMUEL HAMNER, PhD

Director of Product Innovation

Cala Health

Screen Shot 2020-05-21 at 1.59.18 PM.png

JARED HUSTON, MD, FACS

Associate Professor of Surgery

Feinstein Institutes for Medical Research

Zucker School of Medicine

Screen Shot 2020-05-21 at 2.11.59 PM.png

NAVID KHODAPARAST, PhD

Chief Science Officer

Spark Biomedical, Inc.

Screen Shot 2020-05-21 at 2.11.20 PM.png

ELLIOT KRAMES, MD

Founding Editor in Chief,

Neuromodulation

Past President, International Neuromodulation Society

Screen Shot 2020-05-21 at 2.09.42 PM.png

YAAKOV LEVINE, PhD

Director, Applied Research

SetPoint Medical

Screen Shot 2020-05-21 at 2.18.09 PM.png

PEDER OLOFSSON, MD, PhD

Founding Director

Center for Bioelectronic Medicine, Department of Medicine, Karolinska Institutet

Screen Shot 2020-05-21 at 2.08.10 PM.png

LAWRENCE POREE, MD, PhD

Director, Neuromodulation Service, Division of Pain Medicine

University of California, San Francisco

Screen Shot 2020-05-21 at 2.07.31 PM.png

PETER STAATS, MD, PhD

Co-founder and CMO, electroCore

CMO, National Spine and Pain Centers

President-elect, World Institute of Pain

Image-1.png

KRISTL VONCK, MD, PhD

Associate Professor of Neurology

Ghent University, Belgium

General Partners

IMG_3295.jpeg

JOJO PLATT

President,

Platt & Associates, Inc.

Screen Shot 2020-05-22 at 12.55.41 PM.pn

DANIEL POWELL, BBA

CEO

Spark Biomedical, Inc.

ICNC Industry Partners

Cala Health
Cala Health
press to zoom
electroCore
electroCore
press to zoom
Neuronoff
Neuronoff
press to zoom
Soterix Medical
Soterix Medical
press to zoom
Spark Biomedical
Spark Biomedical
press to zoom